Avalon Pharmaceuticals Announces The Initiation Of Drug Discovery Program For The MYC Oncoprotein

... Avalon Pharmaceuticals, Inc. (Nasdaq and NYSE ArcaEx: AVRX), today announced the initiation of a drug discovery program targeting the MYC oncoprotein, one of the most important and previously intractable cancer targets. MYC is one of the most frequently deregulated proteins in human cancer, and is associated with many types of aggressive tumors carrying a poor prognosis. [click link for full article] ...